Nivolumab Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV)
Available Strengths: 40 mg/4 mL (vial); 100 mg/10 mL (vial)
Reference Brands: Opdivo® (EU & US)
Category: Oncology Cancer Care
Nivolumab (brand name Opdivo®) is a monoclonal antibody used in oncology to treat various cancers by blocking the PD-1 receptor, which enhances the immune system’s ability to fight cancer. It is used for melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck cancers, and more. Nivolumab is available in intravenous (IV) form in strengths of 40 mg/4 mL and 100 mg/10 mL. It is available in both the US and EU.
Product Description:
Nivolumab (brand name Opdivo®) is a monoclonal antibody used in oncology as an immune checkpoint inhibitor. It works by targeting and blocking the PD-1 receptor on T-cells, which prevents cancer cells from evading the immune system. By doing so, Nivolumab enhances the body's immune response, allowing T-cells to identify and attack cancer cells more effectively. Nivolumab is indicated for the treatment of several cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and others. It is administered as an intravenous (IV) infusion in two available strengths: 40 mg/4 mL and 100 mg/10 mL.
Nivolumab — third party manufacturing & bulk supply
Nivolumab is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Nivolumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Nivolumab →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Nivolumab is used in the treatment of various types of cancer, including melanoma, non–small cell lung cancer (NSCLC), renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and colorectal cancer. It works as an immune checkpoint inhibitor by blocking the PD-1 receptor, thereby enhancing the immune system’s ability to detect and destroy cancer cells.
Nivolumab is a fully human IgG4 monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It specifically binds to the programmed death-1 (PD-1) receptor on T cells to inhibit its interaction with PD-L1 and PD-L2.
The trade name of Nivolumab is Opdivo.
Nivolumab (Opdivo) is developed and manufactured by Bristol Myers Squibb (BMS).
The generic name is Nivolumab.
The brand name is Opdivo.
Nivolumab is manufactured by Bristol Myers Squibb at its biopharmaceutical production facilities in the United States and Europe, including facilities in Devens (Massachusetts, USA) and Cruiserath (Ireland).
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
